Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rationale: Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing). Objectives: The purpose of this work was to evaluate in animals the smoking cessation agent, varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for its potential as a repurposed drug for disorders of cognition. Methods: Oral doses of varenicline ranging from 0.01 to 0.3 mg/kg were evaluated in aged and middle-aged monkeys for effects on the following: working/short-term memory in a delayed match to sample (DMTS) task, distractibility in a distractor version of the DMTS (DMTS-D), and cognitive flexibility in a ketamine-impaired reversal learning task. Results: In dose-effect studies in the DMTS and DMTS-D tasks, varenicline was not associated with statistically significant effects on performance. However, individualized "optimal doses" were effective when repeated on a separate occasion (i.e., improving DMTS accuracy at long delays and DMTS-D accuracy at short delays by approximately 13.6 and 19.6 percentage points above baseline, respectively). In reversal learning studies, ketamine impaired accuracy and increased perseverative responding, effects that were attenuated by all three doses of varenicline that were evaluated. Conclusions: While the effects of varenicline across the different behavioral tasks were modest, these data suggest that varenicline may have potential as a repurposed drug for disorders of cognition associated with aging (e.g., Alzheimer's disease), as well as those not necessarily associated with advanced age (e.g., schizophrenia).

Original languageEnglish (US)
Pages (from-to)761-771
Number of pages11
JournalPsychopharmacology
Volume233
Issue number5
DOIs
StatePublished - Mar 1 2016

Fingerprint

Macaca nemestrina
Nicotinic Agonists
Task Performance and Analysis
Macaca mulatta
Cognition
Drug Repositioning
Cognition Disorders
Reversal Learning
Ketamine
Neuropsychiatry
Drug Costs
Nicotinic Receptors
Smoking Cessation
Short-Term Memory
Haplorhini
Varenicline
Schizophrenia
Alzheimer Disease
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Attention deficit hyperactivity disorder (ADHD)
  • Cholinergic
  • Cognitive flexibility
  • Mild cognitive impairment
  • Repositioning
  • Repurposing
  • Reversal learning
  • Schizophrenia
  • Working memory

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{6ce18048af574b4d8bb24cf2b2134f9c,
title = "Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys",
abstract = "Rationale: Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing). Objectives: The purpose of this work was to evaluate in animals the smoking cessation agent, varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for its potential as a repurposed drug for disorders of cognition. Methods: Oral doses of varenicline ranging from 0.01 to 0.3 mg/kg were evaluated in aged and middle-aged monkeys for effects on the following: working/short-term memory in a delayed match to sample (DMTS) task, distractibility in a distractor version of the DMTS (DMTS-D), and cognitive flexibility in a ketamine-impaired reversal learning task. Results: In dose-effect studies in the DMTS and DMTS-D tasks, varenicline was not associated with statistically significant effects on performance. However, individualized {"}optimal doses{"} were effective when repeated on a separate occasion (i.e., improving DMTS accuracy at long delays and DMTS-D accuracy at short delays by approximately 13.6 and 19.6 percentage points above baseline, respectively). In reversal learning studies, ketamine impaired accuracy and increased perseverative responding, effects that were attenuated by all three doses of varenicline that were evaluated. Conclusions: While the effects of varenicline across the different behavioral tasks were modest, these data suggest that varenicline may have potential as a repurposed drug for disorders of cognition associated with aging (e.g., Alzheimer's disease), as well as those not necessarily associated with advanced age (e.g., schizophrenia).",
keywords = "Alzheimer's disease, Attention deficit hyperactivity disorder (ADHD), Cholinergic, Cognitive flexibility, Mild cognitive impairment, Repositioning, Repurposing, Reversal learning, Schizophrenia, Working memory",
author = "Terry, {Alvin V} and Marc Plagenhoef and Callahan, {Patrick Michael}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00213-015-4154-0",
language = "English (US)",
volume = "233",
pages = "761--771",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys

AU - Terry, Alvin V

AU - Plagenhoef, Marc

AU - Callahan, Patrick Michael

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Rationale: Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing). Objectives: The purpose of this work was to evaluate in animals the smoking cessation agent, varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for its potential as a repurposed drug for disorders of cognition. Methods: Oral doses of varenicline ranging from 0.01 to 0.3 mg/kg were evaluated in aged and middle-aged monkeys for effects on the following: working/short-term memory in a delayed match to sample (DMTS) task, distractibility in a distractor version of the DMTS (DMTS-D), and cognitive flexibility in a ketamine-impaired reversal learning task. Results: In dose-effect studies in the DMTS and DMTS-D tasks, varenicline was not associated with statistically significant effects on performance. However, individualized "optimal doses" were effective when repeated on a separate occasion (i.e., improving DMTS accuracy at long delays and DMTS-D accuracy at short delays by approximately 13.6 and 19.6 percentage points above baseline, respectively). In reversal learning studies, ketamine impaired accuracy and increased perseverative responding, effects that were attenuated by all three doses of varenicline that were evaluated. Conclusions: While the effects of varenicline across the different behavioral tasks were modest, these data suggest that varenicline may have potential as a repurposed drug for disorders of cognition associated with aging (e.g., Alzheimer's disease), as well as those not necessarily associated with advanced age (e.g., schizophrenia).

AB - Rationale: Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing). Objectives: The purpose of this work was to evaluate in animals the smoking cessation agent, varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for its potential as a repurposed drug for disorders of cognition. Methods: Oral doses of varenicline ranging from 0.01 to 0.3 mg/kg were evaluated in aged and middle-aged monkeys for effects on the following: working/short-term memory in a delayed match to sample (DMTS) task, distractibility in a distractor version of the DMTS (DMTS-D), and cognitive flexibility in a ketamine-impaired reversal learning task. Results: In dose-effect studies in the DMTS and DMTS-D tasks, varenicline was not associated with statistically significant effects on performance. However, individualized "optimal doses" were effective when repeated on a separate occasion (i.e., improving DMTS accuracy at long delays and DMTS-D accuracy at short delays by approximately 13.6 and 19.6 percentage points above baseline, respectively). In reversal learning studies, ketamine impaired accuracy and increased perseverative responding, effects that were attenuated by all three doses of varenicline that were evaluated. Conclusions: While the effects of varenicline across the different behavioral tasks were modest, these data suggest that varenicline may have potential as a repurposed drug for disorders of cognition associated with aging (e.g., Alzheimer's disease), as well as those not necessarily associated with advanced age (e.g., schizophrenia).

KW - Alzheimer's disease

KW - Attention deficit hyperactivity disorder (ADHD)

KW - Cholinergic

KW - Cognitive flexibility

KW - Mild cognitive impairment

KW - Repositioning

KW - Repurposing

KW - Reversal learning

KW - Schizophrenia

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=84958124363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958124363&partnerID=8YFLogxK

U2 - 10.1007/s00213-015-4154-0

DO - 10.1007/s00213-015-4154-0

M3 - Article

VL - 233

SP - 761

EP - 771

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 5

ER -